H&R Block vs Medirom Healthcare Technologies
HRB and MRM side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HRB and MRM compare
H&R Block pays a dividend yielding 3.4%; Medirom Healthcare Technologies does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HRB | MRM |
|---|---|---|
| Size and price | ||
| Market cap | $6.3B | – |
| Share price | $51.31 | $0.330 |
| Change, 1 year | 1.0% | −84.1% |
| Change, 5 years | 103% | −95.3% |
| Beta (5Y) | 0.40 | 0.57 |
| Employees | 4,600 | – |
| StockData Score | ||
| Total score | 18 | – |
| Valuation score | 5 | – |
| Growth score | 3 | – |
| Performance score | 4 | – |
| Health score | 3 | – |
| Dividend score | 3 | – |
| Valuation | ||
| P/E | 9.1× | – |
| P/S | 1.6× | – |
| P/B | 53.8× | – |
| EV/EBITDA | 6.5× | – |
| P/FCF | 8.4× | – |
| PEG | 0.53 | – |
| FCF yield | 12.0% | – |
| Fair value | $78.19 | – |
| Margin of safety | 34.4% | – |
| Growth | ||
| Revenue growth (TTM) | 4.9% | – |
| Revenue growth, 5Y average | 8.4% | – |
| Net income growth (TTM) | 21.1% | – |
| EPS growth (TTM) | 28.9% | – |
| Profitability | ||
| Gross margin | 44.3% | – |
| Net margin | 18.6% | – |
| FCF margin | 19.2% | – |
| Return on equity | 711% | – |
| Financial health | ||
| Debt / equity | 12.69 | – |
| Net debt / EBITDA | 0.50 | – |
| Current ratio | 1.13 | – |
| Altman Z-score | 2.48 | – |
| Piotroski F-score | 7 | – |
| Dividends and buybacks | ||
| Dividend yield | 3.4% | – |
| Payout ratio | 28.8% | – |
| Years of dividend growth | 4 | – |
| Dividend growth, 5Y average | 10.1% | – |
| Shareholder yield | 3.4% | – |
| Ownership | ||
| Held by institutions | 104% | 2.2% |
| Held by insiders | 1.7% | 27.0% |
| Insider net buying, 12 months | −$13.9M | – |
| Short interest, % of float | 15.3% | – |
Go deeper
- HRB stock overview
- HRB income statement
- HRB valuation and score
- MRM stock overview
- MRM income statement
- MRM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.